Who
Dietrich John Pauls
President & CEO
Company insider
Files Form 4 as: President & CEO, DiaMedica Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 5
- Sells
- 0
- Bought
- $113K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Dec 2018
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,200 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Code A | —60,200 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380,000 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —380,000 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 1 Jun 2024filed 3 Jun 2024 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 23 Jun 2023filed 26 Jun 2023 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $50K12,787 at $3.91 | filing |
| 1 Jun 2023filed 2 Jun 2023 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —181,000 at $0.00 | filing |
| 16 Nov 2022filed 16 Nov 2022 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $24K20,000 at $1.21 | filing |
| 1 Jun 2022filed 2 Jun 2022 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —177,000 at $0.00 | filing |
| 16 Aug 2021filed 16 Aug 2021 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $16K5,000 at $3.14 | filing |
| 28 Jul 2021filed 29 Jul 2021 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,000 at $0.00 | filing |
| 1 Jun 2020filed 2 Jun 2020 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —56,000 at $0.00 | filing |
| 16 Aug 2019filed 16 Aug 2019 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,6801,000 at $2.68 | filing |
| 24 Jun 2019filed 26 Jun 2019 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —264,000 at $0.00 | filing |
| 11 Dec 2018filed 11 Dec 2018 | DMAC DiaMedica TherapeuticsBiotechnology | SEC FORM 4 Bought | $20K5,000 at $4.00 | filing |
News
No headline names them, or the companies they trade most, lately.